Targeting the USP7-CDK1 axis suppresses estrogen receptor-positive breast cancer progression
Targeting the USP7-CDK1 axis suppresses estrogen receptor-positive breast cancer progression
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Estrogen receptor-positive breast cancer (ERPBC) accounts for approximately 70% of breast cancers in women worldwide. The therapeutic strategy process for ERPBC is well-established and significantly reduces the mortality rate. The discovery of new therapeutic targets remains essential for ERPBC patients with metastasis or endocrine resistance. This...
Alternative Titles
Full title
Targeting the USP7-CDK1 axis suppresses estrogen receptor-positive breast cancer progression
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_c7c459cc30b6452980626c9a12b261cd
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_c7c459cc30b6452980626c9a12b261cd
Other Identifiers
ISSN
1475-2867
E-ISSN
1475-2867
DOI
10.1186/s12935-025-03693-2
